$AZN

AstraZeneca, FDC, Nutricia, and others reported strong sales growth in September 2026, per Pharmarack data. AstraZeneca saw 25.1% MAT value growth and 38.1% monthly value growth. FDC and Nutricia also posted significant gains. Sun Pharma maintained its top position with 15.1% MAT value growth. The Indian Pharmaceutical Market grew 13.5% in value and 2.9% in units monthly.

RBC maintains 'outperform' rating on AstraZeneca (AZN) with a 14,500p target, expecting Q3 revenue of $16.3B, 1.8% above consensus, and core EPS of $2.61. Oncology sales are forecast at $7.1B, led by Tagrisso. Farxiga and Lynparza sales are below consensus. Operating expenses are forecast at $7.9B. The AVANZAR trial is a key catalyst.

RBC Capital Markets assigned a Buy rating to AstraZeneca PLC (AZN) based on a weighted average of ratings including valuation, EPS revisions, and visibility. The company also announced a collaboration with insitro on an AI system. AZN's stock has seen a 5.77% increase year-to-date.

insitro and AstraZeneca have formed a research collaboration to discover novel therapeutics for MASH and cardiomyopathies. insitro will receive $40 million upfront and up to $1.46 billion in milestones. insitro's AI platform will identify disease biology, while AstraZeneca will lead clinical development and commercialization.

NIPER Raebareli and AstraZeneca India signed an MoU to enhance clinical research in India, expanding trials to 25 new sites. The partnership, supported by the Department of Pharmaceuticals, aims to train workforce and improve site readiness, aligning with Biopharma SHAKTI's goal of 1,000 trial sites.

AstraZeneca PLC (AZN) shares rose 4.0% to $162.03 on October 14, 2026. The stock is trading 10.7% below its fair value estimate of $181.41, according to GF Value™. AZN's GF Score™ is 76/100, indicating strong profitability and growth, but weak momentum. Insiders have net sold $2.2M in the past year. The P/E ratio is 24.2x, below its 5-year median of 33.2x.

AstraZeneca invested $2B in Summit Therapeutics, acquiring 12% equity. The deal focuses on ivonescimab, a PD-1/VEGF bispecific antibody, for use in TNBC and GI cancers. The investment aims to advance ADC combinations in oncology. According to a healthcare executive, the biology is compelling but key questions remain on efficacy and toxicity.

AstraZeneca PLC (NYSE: AZN) stock rose 4.02% after positive late-stage oncology trial results. Analysts upgraded the stock, with Nordea and Citi raising price targets. The company's revenue is $58.7B, with strong margins. AZN is expanding its oncology portfolio through deals, including a $2B equity agreement with Summit Therapeutics. Chinese regulators approved Datroway for triple-negative breast cancer, broadening its global reach.

AstraZeneca (AZN) completed the LAZURE Phase II trial, testing AZD0780 with rosuvastatin against a placebo plus rosuvastatin to assess LDL cholesterol reduction. The double-blind study aims to support future combo therapies. Results could impact AZN's cardiovascular pipeline and competitors in the lipid management market.

AstraZeneca's stock rose 3.7% to $161.59 on Wednesday, defying broader market declines. The company's shares had been near a 52-week low. Analysts cited defensive sector rotation, a double upgrade, and easing UK rate fears as drivers. AstraZeneca reported strong H1 2026 earnings with 11% core EPS growth and expanding margins. Oncology revenue grew 15%, while the full-year 2025 revenue was $58.7 billion. The stock's recent low valuation and high-quality growth profile attracted buyers.